![](https://sourceonhealth.wpenginepowered.com/wp-content/uploads/2019/04/SLIHCQ-title-1.png)
HB 162 – Maryland
Status: Inactive / DeadYear Introduced: 2021
Link: http://mgaleg.maryland.gov/mgawebsite/Legislation/Details/HB0162?ys=2021RS
Altering a certain requirement that the Prescription Drug Affordability Board, in conjunction with a certain council, draft a certain plan for setting upper payment limits for prescription drug products; altering the date by which the Board is required to submit the plan to a certain committee of the General Assembly; requiring, rather than authorizing, the Board to set upper payment limits for certain prescription drug products and altering the date by which the limits are to be set to on or after February 1, 2022; etc.
Key Issues:
PHARMACEUTICALS
Drug Pricing
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
Associated Litigation:
No items found